SCHEDULE: Farallon Capital Exits Centessa Pharmaceuticals Position

Farallon Capital Management and associated individuals have reported the disposal of their entire stake in Centessa Pharmaceuticals following its acquisition by Eli Lilly.

Summary

• Farallon Capital Management, L.L.C. and its associated reporting persons have disposed of all previously held Ordinary Shares of Centessa Pharmaceuticals plc.
• The disposal occurred on June 24, 2026, coinciding with the completion of the acquisition of Centessa Pharmaceuticals by Eli Lilly and Company.
• The reporting persons now hold 0% of the outstanding Ordinary Shares of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the completion of a previously announced acquisition.

Positives

• The exit of the investment aligns with the successful completion of a corporate acquisition by a major pharmaceutical entity, Eli Lilly and Company.

Negatives

• The reporting persons no longer maintain any equity interest in Centessa Pharmaceuticals.

Risks

• None, as the reporting persons have fully divested their interest in the issuer.

Future Outlook

No future outlook is provided as the reporting persons have fully exited their position in the issuer.

Industry Context

StockSavvy.ai notes that this filing confirms the finalization of a significant M&A event in the biotechnology sector, where Eli Lilly continues its strategy of acquiring specialized pharmaceutical companies to bolster its pipeline.

Comparison to Industry Standards

• The exit of institutional investors following a successful acquisition is standard practice in the pharmaceutical M&A landscape.
• The transaction follows typical regulatory disclosure requirements for institutional investors exiting a position post-acquisition.

Stakeholder Impact

• Shareholders of Centessa Pharmaceuticals have been impacted by the acquisition by Eli Lilly.

Next Steps

• None, as the reporting persons have fully divested.

Key Dates

Keywords

Centessa Pharmaceuticals, Farallon Capital, Eli Lilly, Acquisition, Divestment, Schedule 13D